Investigation Report on the Chinese Thymopentin Market 2018: Analysis through 2013 to 2022 –

The “Investigation
Report on Chinese Thymopentin Market, 2018-2022” report has
been added to’s offering.

In 1985, Thymopentin for Injection was launched in Italy in the trade
name of “Timunox”. In 1997, Hainan Zhonghe Pharmaceutical Co., Ltd.
first launched Thymopentin for Injection (trade name: Hexin), China’s
first two-way immunomodulator of synthetic polypeptide after independent
research and development. The product once played an important role in
the fight against SARS in 2003.

Later, other enterprises including Beijing SL Pharmaceutical Co., Ltd.
were approved to produce Thymopentin. Because of a low technological
barrier, there are many manufacturers and fierce competitions in the
market. Thymopentin is only sold in China as a Chinese-style drug.

According to research, in 2017, the sales value of Thymopentin exceeded
CNY 1 billion in the Chinese market dominated by Hainan Zhonghe
Pharmaceutical Co., Ltd., Beijing SL Pharmaceutical Co., Ltd., Beijing
Sciecure Pharmaceutical Co., Ltd. and Hybio Pharmaceutical Co., Ltd.

The sales value of top 10 enterprises took up about 99% of the market.
The sales value of Hainan Zhonghe ranked first with a market share over
30%. It is expected that the Chinese Thymopentin still has large
potential to grow in the coming years.

Companies Featured

Key Topics Covered

1 Relevant Concepts of Thymopentin

2 Market Overview of Thymopentin in China

3 Sales of Thymopentin in China, 2013-2017

4 Investigation on Market Share of Major Thymopentin Manufacturers in
China, 2013-2017

5 Thymopentin in Different Dosage Forms, 2013-2017

6 Reference Sale Price of Major Thymopentin Products in Chinese Market,

7 Major Thymopentin Manufacturers in China, 2013-2017

8 Prospects of Chinese Thymopentin Market, 2018-2022

For more information about this report visit

View source version on

Leave a Comment